69454

HMS174(DE3)pLysS Competent Cells - Novagen

Escherichia coli, rod shaped

• UNSPSC Code: 41106202
• NACRES: NA.81
• Biological source: Escherichia coli
• Growth mode: adherent or suspension
• Morphology: rod shaped
• Manufacturer/tradename: Novagen^®

Właściwości

• Nazwa produktu: HMS174(DE3)pLysS Competent Cells - Novagen, HMS174 strains provide high transformation efficiencies and the recA mutation in a K-12 background. T7 lysozyme expression suppresses basal T7 expression.
• biological source: Escherichia coli
• Quality Segment: 100
• manufacturer/tradename: Novagen^®
• storage condition: OK to freeze, avoid repeated freeze/thaw cycles
• growth mode: adherent or suspension
• morphology: rod shaped
• technique(s): microbiological culture: suitable
• cell transformation: transformation efficiency: >5×10⁶ cfu/μg
• shipped in: dry ice
• storage temp.: −70°C

Opis

General description

Genotype: F^-recA1 hsdR(r_K12^- m_K12⁺) (DE3) pLysS (Cam^R, Rif ^R)

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.

HMS174 strains provide the recA mutation in aK-12 background. Like BLR, these strains maystabilize certain target genes whose productsmay cause the loss of the DE3 prophage.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.

HMS174 strains provide high transformation efficiencies and the recA mutation in a K-12 background. T7 lysozyme expression suppresses basal T7 expression.

Other Notes

0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlHMS174(DE3)pLysS Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•2 ng2 ngTest Plasmid

Legal Information

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the “EMD Product”) requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: [email protected].

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 10 - Combustible liquids
• wgk: WGK 2